The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
02/04/2013
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
APS-OAA-13-000001
Opportunity Category:
Discretionary
Posted Date:
Feb 04, 2013
Creation Date:
Feb 04, 2013
Original Closing Date for Applications:
Mar 18, 2013
Current Closing Date for Applications:
Mar 18, 2013
Archive Date:
Apr 17, 2013
Funding Instrument Type:
Cooperative Agreement
Category of Funding Activity:
Health
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
Award Ceiling:
$168,000,000
Award Floor:
$0
CFDA Number(s):
98.001
--
USAID Foreign Assistance for Programs Overseas
Cost Sharing or Matching Requirement:
Yes
Eligible Applicants
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Additional Information on Eligibility:
Agency Name
Agency for International Development
Description
The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction.
Link to Additional Information
If you have difficulty accessing the full announcement
electronically, please contact:
